Femasys Inc. reported its financial results for the third quarter of 2025, revealing a revenue increase of 31.4% to $729,394 compared to $554,908 in the same period last year. For the nine months ending September 30, 2025, total sales reached $1,479,926, a 41.3% increase from $1,047,532 in the prior year. Despite this growth, the company incurred a net loss of $4,194,821 for the quarter, a 22.4% improvement from the loss of $5,408,860 in Q3 2024. The nine-month net loss also increased slightly to $14,677,582 from $13,692,944 year-over-year.
The company’s operating expenses decreased by 25.4% to $4,089,324 for the third quarter, primarily due to reduced research and development costs, which fell by 40% to $1,382,022. This reduction was attributed to the commercialization of products and lower clinical and professional fees. Sales and marketing expenses also decreased by 27.2%, reflecting a strategic shift in resource allocation. However, the cost of sales rose by 54% to $293,838, driven by increased product sales.
Femasys has made significant strides in its product offerings, including the launch of FemSperm™, a kit designed to enhance its infertility portfolio, and the FemBloc® permanent birth control system, which has received regulatory approvals in several international markets. The company announced partnerships for distribution in Europe and is advancing its clinical trials for FemBloc in the U.S. The company’s total assets increased to $16,290,153 as of September 30, 2025, up from $12,445,002 at the end of 2024, largely due to increased cash reserves and inventory.
As of the end of September 2025, Femasys had cash and cash equivalents of $4,569,038, which the company anticipates will support operations into September 2026. However, the company has expressed concerns regarding its ability to continue as a going concern, citing the need for additional financing to support ongoing operations and product development. The company plans to pursue various financing options, including equity and debt, to fund its commercialization efforts and clinical trials.
Looking ahead, Femasys expects to continue incurring significant losses as it invests in the commercialization of its products and the advancement of its clinical trials. The company remains focused on expanding its market presence and achieving regulatory approvals for its product candidates, while also managing its financial resources to ensure operational sustainability.
About FEMASYS INC
Femasys Inc. develops women’s health solutions, including non-surgical permanent birth control, artificial insemination, and diagnostic devices. Its products serve infertility and contraception markets worldwide, offering minimally invasive, cost-effective alternatives to surgery and traditional treatments. With a strong patent portfolio and regulatory approvals, the company focuses on innovative, in-office medical devices that improve safety, accessibility, and patient satisfaction in reproductive health.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.